The iLink® Procedure

iLink®️️️️️ Corneal Cross-Linking

iLink® corneal cross-linking is an innovative therapy that has transformed the treatment of progressive keratoconus. This minimally invasive outpatient procedure uses Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) riboflavin eye drops, combined with ultraviolet light from the KXL system to1:

  • Create new corneal collagen cross-links
  • Shorten and thicken collagen fibrils
  • Stiffen and strengthen the cornea
Contact Representative

Solutions For Healthcare Providers

Solutions For Healthcare Providers

Transforming the Standard of Care for Progressive Keratoconus

iLink® is the first and only FDA-approved corneal cross-linking procedure that slows or halts the progression of keratoconus and helps preserve vision.

Watch this video for unique patient and doctor perspectives about progressive keratoconus and learn how this underserved patient population with a rare and sight-threatening condition is treated with iLink® corneal cross-linking.

Contact Representative

Explore The Results of Our Clinical Study Data

In clinical studies, cross-linking–treated eyes showed increasing improvement in Kmax from month 3 through month 12, while in untreated, sham eyes, Kmax demonstrated steepening.4

View Clinical Data

If it’s not iLink®, it’s not FDA approved

When it comes to referring patients with progressive keratoconus for treatment, iLink® is the only FDA-approved corneal cross-linking procedure.

Learn More

Explore Patient Resources for Keratoconus
Treatment Options

View Patient Website

Reimbursement Support

Access Solutions

Looking for reimbursement info? GPS (Glaukos Patient Services) provides strategic and trustworthy market access solutions for all Glaukos procedures and products in glaucoma, corneal health, and retinal disease care.

Reimbursement Info

Resources for Healthcare Professionals

Learn More About iLink® from the Experts

Order print versions of our practice marketing materials, including educational resources on keratoconus and FDA-approved cross-linking. You can also download digital versions of many of our educational resources.

View Resources

Contact Us Today
to Integrate the iLink®
Procedure Into Your

Explore additional information about iLink® in our digital brochure and learn how the procedure is transforming the standard of care for progressive keratoconus.

More Info

"*" indicates required fields

This field is for validation purposes and should be left unchanged.


  • Beshtawi IM, O’Donnell C, Radhakrishnan H. Biomechanical properties of corneal tissue after ultraviolet-A-riboflavin crosslinking. J Cataract Refract Surg. 2013;39(3):451–462.
  • Pramanik S, Musch DC, Sutphin JE, Farjo AA. Extended long-term outcomes of penetrating keratoplasty for keratoconus. Ophthalmology. 2006;113(9):1633-1638.
  • Maharana PK, Agarwal K, Jhanji V, Vajpayee RB. Deep anterior lamellar keratoplasty for keratoconus: a review. Eye Contact Lens. 2014;40(6):382-389.
  • Photrexa [package insert]. Waltham, MA: Glaukos, Inc. 2016.

Please Select Your Country


Using Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution), and the KXL® System, the iLink® corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.*1

[Photrexa IFU/p1/col1/para3/lines1-4]

Important Safety Information

Corneal collagen cross-linking should not be performed on pregnant women.

Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects. The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.

These are not all the side effects of the corneal collagen cross-linking treatment. For more information, go to Prescribing Info to obtain the FDA-approved product labeling.

You are encouraged to report all side effects to the FDA. Visit, or call 1-800-FDA-1088.

*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL® System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.


Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.


1. Photrexa Prescribing Information. Burlington, MA: Avedro, a Glaukos company 2022